Nyheder

Bavarian banker frem efter tysk ordre

Signe Terp

An employee of the vaccine company Bavarian Nordic shows a container with fibroblast cells from chicken embryos for the propagation of vaccine viruses in a laboratory of the company in Martinsried near Munich, Germany, May 24, 2022. The company, headquartered in Denmark, is the only one in the world to have approval for a smallpox vaccine called Jynneos in the U.S. and Imvanex in Europe, which is also effective against monkeypox. REUTERS/Lukas Barth?
An employee of the vaccine company Bavarian Nordic shows a container with fibroblast cells from chicken embryos for the propagation of vaccine viruses in a laboratory of the company in Martinsried near Munich, Germany, May 24, 2022. The company, headquartered in Denmark, is the only one in the world to have approval for a smallpox vaccine called Jynneos in the U.S. and Imvanex in Europe, which is also effective against monkeypox. REUTERS/Lukas Barth? Foto: LUKAS BARTH
Vis mere

Vaccineselskabet Bavarian Nordic suser frem på børsen og er oppe med 8,4 pct.

Den hæsblæsende medvind kommer ovenpå gårsdagens røde dag for Bavarian, hvor der på få timer blev barberet 2,5 mia. af markedsværdien. Det skete ovenpå en melding fra Verdenssundhedsorganisationen, WHO, som gjorde investorerne pessimistiske.

Meldingen gik på, at det ifølge WHO ikke vil være nødvendigt at massevaccinere mod abekopper.

Det, der sandynligvis er vand på Bavarians mølle onsdag er, at Tyskland har bestilt 40.000 doser af abekoppevaccinen hos selskabet.

Læs også: Hastemøde i den russiske centralbank

Læs også: Nu køber Tyskland vacciner hos Bavarian